Valuation dashboard for Becton, Dickinson and Company (BDX) with P/E 59.60, P/B 2.23, EV/EBITDA 15.70 and dividend yield 2.01%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products.
Analysis Summary
Becton, Dickinson and Company reported revenue of $21.84B in the most recent fiscal year, growing at a 5-year CAGR of 6.3%. Net income reached $1.68B, with a 13.9% 5-year CAGR.
Trailing-twelve-month margins: gross margin 46.1%, operating margin 9.8%, net margin 4.5%.
At $197.88 (closing price, October 30, 2026), BDX trades at a P/E of 59.60 and an ROE of 3.79%. Market capitalisation stands at $53.9B, placing it among large-cap names.
Balance sheet quality for BDX: current ratio of 1.1. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 59.60 |
| Price / Book | 2.23 |
| EV / EBITDA | 15.70 |
| Dividend Yield | 2.01% |
Valuation Models
| DCF Fair Value | $690.97 |
| vs Current Price | +249.2% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| BDX | Becton, Dickinson and Company | $53.9B | 59.60 | 2.23 | 3.8% |
| MMSI | Merit Medical Systems, Inc. | $5.2B | 32.42 | 2.96 | 9.7% |
| ICUI | ICU Medical, Inc. | $4.1B | 138.80 | 1.90 | 1.4% |
| ABT | Abbott Laboratories | $183.8B | 39.33 | 3.61 | 9.1% |
| MDT | Medtronic Plc | $123.5B | 23.78 | 2.46 | 10.6% |
| WST | West Pharmaceutical Services, Inc. | $28.7B | 46.31 | 9.79 | 21.1% |
| SOLV | Solventum Corporation | $13.8B | 9.93 | 2.94 | 29.0% |
| BAX | Baxter International Inc. | $11.9B | 1.83 | -11.6% |
Price
| Price | $197.88 (closing price, October 30, 2026) |
| Market Cap | $53.9B |
| Exchange | NYSE |
| Country | US |
Profitability
| Return on Equity | 3.79% |
| Return on Invested Capital | 3.72% |
| Return on Assets | 1.85% |
| Gross Margin | 46.12% |
| Operating Margin | 9.83% |
| Net Margin | 4.52% |
Related companies: MMSI · ICUI · ABT · MDT · WST · SOLV · BAX · TFX
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of BDX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks